New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of ...
Hosted on MSN1mon
AstraZeneca Rises Almost 9% in a Month: How to Play the StockRare Disease and CVRM segments in 2025. AstraZeneca believes that outside China. Farxiga and Lynparza sales should continue to grow due to continued market leadership. Backed by its new products ...
Late last year, pharmaphorum spoke with AstraZeneca’s Ben Challis, VP and head of translational science and experimental medicine, cardiovascular, renal, and metabolism (CVRM), together with ...
Zacks Investment Research on MSN2mon
AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?AstraZeneca AZN stock has declined 14% in the past three months. A lot of this price decline is due to ongoing investigations at its China subsidiary. However, the overall drug and biotech sector has ...
Cardiovascular, renal, and metabolism (CVRM) wasn't far behind with 20% growth. AstraZeneca also proffered guidance for full-year 2025 in its earnings report. The company is estimating that its ...
AstraZeneca PLC (NASDAQ ... Its core therapeutic areas include oncology, cardiovascular, renal and metabolism (CVRM), respiratory, and rare diseases. The company has a strong pipeline and product ...
March 21 (UPI) --AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational pharmaceutical announced Friday. The investment will mark the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback